• 목록

7th IVRA International Conference on Hyperthermia in Medicine Successfully Concludes in Jakarta on December 1

On Sunday, December 1, the Grand Ballroom of the JS Luwansa Hotel & Convention Center in Jakarta, Indonesia, hosted the 7th IVRA International Medical Conference Indonesia, where the latest research and clinical applications of hyperthermia therapy in cancer treatment were presented.

The conference, held under the theme “Hyperthermia in Oncology: Where Are We Now?”, brought together leading global experts in hyperthermia to present treatment outcomes and shed light on the current state and future of hyperthermia as a cancer therapy.

Speakers from a wide range of countries—including Korea, Malaysia, Singapore, Indonesia, and Australia—participated in the event. Notable presenters included Mr. Sung-Ho Han, CEO of AdipoLabs (Korea), Prof. Eui-Sin Kim of MD Anderson and Seoul National University, Prof. Hong-Seok Jang and Prof. Kyu-Hye Choi of Seoul St. Mary’s Hospital, Dr. Seung-Mo Yoo of Yesan Myongji Hospital, Dr. Chan-Yong Lee of Seoul OnCare Clinic, and Dr. Hyung-Jin Shin of EM365 Clinic in Hwaseong. From overseas, distinguished speakers included Dr. Jayendran Dharmaratnam, Mr. Michael Loone, and Dr. Kenny Yong Yean Sim (Malaysia); Dr. Brendan Chia Seng Hup and Dr. Deibby Mamahit (Singapore); Prof. Dr. Agus Purwadianto and Dr. Widya Murni (Indonesia); and Dr. Taufiq Binjemain (Australia). More than 300 Indonesian cancer specialists also took part, sharing insights into the effects and case studies of hyperthermia therapy.

The conference was chaired by Dr. Cosphiadi Irawan, Dr. Demak Lumban Tobing, Prof. Laksono Trisnantoro, and Dr. Handoko from Indonesia, along with Dr. Zawawi Abdulla from Malaysia, who led the discussions.

In a special gesture, the Korean musical duo Norazo, who have been volunteering annually to support cancer patients, attended the conference and joined the gala dinner in solidarity with the cause.

AdipoLabs’ flagship product, the Remission 1℃ Radiofrequency Hyperthermia System, received approval from the Korean Ministry of Food and Drug Safety in October 2015 for cancer treatment. It has also obtained CE certification in Europe, Halal certification, and MDA approval in Malaysia. The device delivers 0.46 MHz of radiofrequency energy into the human body, producing deep frictional heat that safely raises body temperature to 42°C, thereby maximizing the therapeutic effects of hyperthermia against cancer.

By generating deep tissue heat through RF conduction, the device induces necrosis in heat-sensitive cancer cells, offering new hope for cancer patients both in Korea and abroad.

Mr. Sung-Ho Han, CEO of AdipoLabs, stated:

“Hyperthermia therapy is rapidly advancing as a cancer treatment modality and is greatly contributing to improving patients’ quality of life. Through this conference, experts from various countries have shared the latest research and clinical findings, demonstrating that hyperthermia therapy is establishing itself as a practical and effective treatment in the global medical field.”

The conference aimed to explore the potential of hyperthermia as a cancer therapy, enhance treatment effectiveness, and improve patients’ quality of life. By sharing the latest technologies and research outcomes, it also served as an important opportunity to strengthen collaboration among international medical experts.